ALNY Alnylam Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALNY

Price (delayed)

$165.04

Market cap

$22.11B

P/E Ratio

8.1

Dividend/share

N/A

EPS

$20.38

Enterprise value

$23.35B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 98

Alnylam has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and ...

Highlights
The equity has soared by 166% from the previous quarter
The stock's price to earnings (P/E) is 89% less than its last 4 quarters average of 74.2
The company's quick ratio fell by 19% QoQ and by 4.6% YoY
The company's gross margin fell by 8% YoY and by 3% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.alnylam.com
Peers: ARWR REGN SRPT OPK

Key stats

What are the main financial stats of ALNY

ALNY stock price

How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
5.36%
1 week
5.84%
1 month
-26.26%
1 year
-63.65%
YTD
-58.5%
QTD
-33.11%

Financial performance

How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$5.01B
Gross profit
$3.87B
Operating income
$977.59M
Net income
$2.72B
Gross margin
77.3%
Net margin
54.3%
The company's operating margin has surged by 138% YoY but it fell by 6% QoQ
The company's revenue has surged by 56% YoY and by 4.4% QoQ
The gross profit is up by 44% YoY
The company's gross margin fell by 8% YoY and by 3% QoQ

Price vs fundamentals

How does ALNY's price correlate with its fundamentals

Growth

What is Alnylam Pharmaceuticals's growth rate over time

Valuation

What is Alnylam Pharmaceuticals stock price valuation
P/E
8.1
P/B
6.13
P/S
4.41
EV/EBIT
19.11
EV/EBITDA
18.28
EV/Sales
4.66
The stock's price to earnings (P/E) is 89% less than its last 4 quarters average of 74.2
The equity has soared by 166% from the previous quarter
ALNY's price to book (P/B) is 83% less than its last 4 quarters average of 36.6
ALNY's price to sales (P/S) is 73% lower than its 5-year quarterly average of 16.5 and 55% lower than its last 4 quarters average of 9.8
The company's revenue has surged by 56% YoY and by 4.4% QoQ

Efficiency

How efficient is Alnylam Pharmaceuticals business performance
ALNY's return on sales has surged by 190% year-on-year
The return on assets has surged by 178% since the previous quarter
The ROE has soared by 125% YoY and by 62% from the previous quarter
ALNY's return on invested capital is down by 7% since the previous quarter

Dividends

What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNY.

Financial health

How did Alnylam Pharmaceuticals financials performed over time
The total assets is 82% more than the total liabilities
The total assets has soared by 65% YoY and by 44% from the previous quarter
Alnylam Pharmaceuticals's current ratio has decreased by 19% from the previous quarter and by 2.4% YoY
The debt is 17% less than the equity
The equity has soared by 166% from the previous quarter
Alnylam Pharmaceuticals's debt to equity has plunged by 94% YoY and by 62% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.